2020
Alterations in Ki67 Labeling Following Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Vyas M, Tang L, Rekhtman N, Klimstra D. Alterations in Ki67 Labeling Following Treatment of Poorly Differentiated Neuroendocrine Carcinomas. The American Journal Of Surgical Pathology 2020, 45: 25-34. PMID: 33177340, PMCID: PMC8549487, DOI: 10.1097/pas.0000000000001602.Peer-Reviewed Original ResearchConceptsHigh-grade neuroendocrine neoplasmsWD-NETsKi67 indexPD-NECsPoor-differentiated neuroendocrine carcinomasWell-differentiated neuroendocrine tumorsTreatment-associated alterationsSemi-quantitative scoreLow Ki67WHO G1Neuroendocrine carcinomaAdenoneuroendocrine carcinomaNeuroendocrine tumorsNeuroendocrine neoplasmsPrognostic significanceG2 gradeKi67 labelingDiagnostic pitfallsWHO gradePosttreatment groupStudy cohortAnatomical sitesKi67Pretreatment groupPosttreatment samples
2016
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas
Tang L, Basturk O, Sue J, Klimstra D. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. The American Journal Of Surgical Pathology 2016, 40: 1192-1202. PMID: 27259015, PMCID: PMC4988129, DOI: 10.1097/pas.0000000000000662.Peer-Reviewed Original ResearchConceptsHigh-grade pancreatic neuroendocrine neoplasmsAbnormal expression of p53PD-NECsWD-NETsPancreatic neuroendocrine neoplasmsNeuroendocrine neoplasmsExpression of p53Loss of DAXXNeuroendocrine carcinomaPoor-differentiated neuroendocrine carcinomasHigh-grade neuroendocrine neoplasmsAccurate diagnosisEvaluate immunohistochemical stainingG3 neuroendocrine neoplasmsHigh-grade progressionWHO grade 3Hematoxylin and eosin sectionsDisease-specific survivalAbnormal expressionGroup of tumorsDegree of diagnostic concordanceWHO classification schemeATRX protein expressionCoexisting adenocarcinomaAbnormal p53Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas
Tang L, Untch B, Reidy D, O'Reilly E, Dhall D, Jih L, Basturk O, Allen P, Klimstra D. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clinical Cancer Research 2016, 22: 1011-1017. PMID: 26482044, PMCID: PMC4988130, DOI: 10.1158/1078-0432.ccr-15-0548.Peer-Reviewed Original ResearchConceptsDisease-specific survivalWD-NETsPD-NECsHigh-grade componentNeuroendocrine tumorsGroup of aggressive neoplasmsMedian disease-specific survivalPoor-differentiated neuroendocrine carcinomasHigh-grade neuroendocrine neoplasmsHigh-grade NECsHigh-grade neoplasmsLow-intermediate gradeGene mutation analysisMetastatic sitesNeuroendocrine carcinomaPrimary tumorNeuroendocrine neoplasmsProliferative indexAggressive neoplasmClinical presentationDismal outcomeRadiographic featuresHigh-gradeBile ductPrimary site
2015
The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
Klimstra D, Beltran H, Lilenbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. American Society Of Clinical Oncology Educational Book 2015, 92-103. PMID: 25993147, DOI: 10.14694/edbook_am.2015.35.92.Peer-Reviewed Original ResearchConceptsWD-NETsSite of originPD-NECsNeuroendocrine neoplasmsTreated with platinum-based chemotherapyFeatures of neuroendocrine neoplasmsTreatment of unresectable diseaseSpectrum of neuroendocrine tumorsAggressive clinical coursePlatinum-based chemotherapyFamily of neoplasmsUnresectable diseaseSurgical resectionNeuroendocrine differentiationNeuroendocrine tumorsNeuroendocrine phenotypeClinical courseProstate glandNeoplasia syndromeNon-neoplastic neuroendocrine cellsHistological classificationGenetic alterationsClinical managementAnatomical sitesHistological evidencePoorly Differentiated Neuroendocrine Carcinoma of the Pancreas
Basturk O, Klimstra D. Poorly Differentiated Neuroendocrine Carcinoma of the Pancreas. 2015, 147-153. DOI: 10.1007/978-3-319-17235-4_17.Peer-Reviewed Original ResearchPD-NECsNeuroendocrine tumorsNeuroendocrine carcinomaPoor-differentiated neuroendocrine carcinomasKi-67 labeling indexDegree of mitotic activityCell neuroendocrine carcinomaWHO classification systemCell carcinomaTumor entitiesPancreatic carcinomaKi-67Labeling indexRb/p16 pathwayFatal tumorCarcinomaGenetic changesTumorMitotic activityImmunohistochemical labelingPancreasGastrointestinal tractLung
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply